Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study

被引：0
|
作者：
William B. Young
J. Ivan Lopez
John F. Rothrock
Amelia Orejudos
Aubrey Manack Adams
Richard B. Lipton
Andrew M. Blumenfeld
机构：
[1] 900 Walnut Street,Jefferson Hospital for Neuroscience
[2] Second Floor,Montefiore Headache Center, Department of Neurology, Department of Epidemiology and Population Health
[3] Suite #200,Headache Center of Southern California
[4] University of South Alabama College of Medicine,undefined
[5] George Washington School of Medicine,undefined
[6] Allergan plc,undefined
[7] Albert Einstein College of Medicine,undefined
[8] The Neurology Center,undefined
来源：
The Journal of Headache and Pain | 2019年 / 20卷
关键词：
COMPEL; onabotulinumtoxinA; Migraine; Allodynia; Disability; Quality of life;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study
    Young, William B.
    Lopez, J. Ivan
    Rothrock, John F.
    Orejudos, Amelia
    Adams, Aubrey Manack
    Lipton, Richard B.
    Blumenfeld, Andrew M.
    JOURNAL OF HEADACHE AND PAIN, 2019, 20 (1):
  • [2] Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study
    Young, William B.
    Lopez, J. Ivan
    Rothrock, John F.
    Orejudos, Amelia
    Adams, Aubrey Manack
    Lipton, Richard B.
    Blumenfeld, Andrew M.
    JOURNAL OF HEADACHE AND PAIN, 2019, 20 (1):
  • [3] Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study
    William B. Young
    J. Ivan Lopez
    John F. Rothrock
    Amelia Orejudos
    Aubrey Manack Adams
    Richard B. Lipton
    Andrew M. Blumenfeld
    The Journal of Headache and Pain, 2019, 20
  • [4] EFFECTS OF ONABOTULINUMTOXINA ON HEADACHE FREQUENCY AND IMPACT IN PATIENTS WITH CHRONIC MIGRAINE WITH OR WITHOUT BASELINE ALLODYNIA: A COMPEL SUBANALYSIS
    Young, W. B.
    Rothrock, J. F.
    Lopez, J. I.
    Adams, A. Manack
    Lipton, R. B.
    Blumenfeld, A. M.
    CEPHALALGIA, 2018, 38 : 76 - 78
  • [5] Effects of OnabotulinumtoxinA Treatment on Disability and Quality of Life in Patients with Chronic Migraine with Baseline Allodynia: A COMPEL Subanalysis
    Young, William B.
    Lopez, J. Ivan
    Rothrock, John F.
    Adams, Aubrey Manack
    Blumenfeld, Andrew M.
    CEPHALALGIA, 2017, 37 : 100 - 101
  • [6] Effects of OnabotulinumtoxinA Treatment on Disability and Quality of Life in Patients with Chronic Migraine with Baseline Allodynia: A COMPEL Subanalysis
    Young, William B.
    Rothrock, John F.
    Lopez, J. Ivan
    Adams, Aubrey Manack
    Blumenfeld, Andrew M.
    NEUROLOGY, 2018, 90
  • [7] Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study
    Winner, Paul K.
    Blumenfeld, Andrew M.
    Eross, Eric J.
    Orejudos, Amelia C.
    Mirjah, Debbie L.
    Adams, Aubrey Manack
    Brin, Mitchell F.
    DRUG SAFETY, 2019, 42 (08) : 1013 - 1024
  • [8] EFFECTS OF ONABOTULINUMTOXINA TREATMENT ON HEADACHE FREQUENCY, INTENSITY, AND IMPACT IN PATIENTS WITH AND WITHOUT DAILY HEADACHES AT BASELINE: A COMPEL SUBANALYSIS
    Lopez, J. I.
    Blumenfeld, A. M.
    Young, W. B.
    Adams, A. Manack
    Lipton, R. B.
    Rothrock, J. F.
    CEPHALALGIA, 2018, 38 : 79 - 81
  • [9] Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study
    Paul K. Winner
    Andrew M. Blumenfeld
    Eric J. Eross
    Amelia C. Orejudos
    Debbie L. Mirjah
    Aubrey Manack Adams
    Mitchell F. Brin
    Drug Safety, 2019, 42 : 1013 - 1024
  • [10] Benefits of Long-Term OnabotulinumtoxinA Treatment in Chronic Migraine: Results From the COMPEL Study
    Blumenfeld, A. M.
    Luo, L.
    Yedigarova, L.
    Lipton, R. B.
    HEADACHE, 2020, 60 : 101 - 101
12345